# Kernal Biologics

**Source:** https://geo.sig.ai/brands/kernal-biologics  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** kernalbio.com  
**Last Updated:** 2026-04-14

## Summary

AI-designed mRNA 2.0 therapeutics for in vivo CAR-T cancer and autoimmune therapy; $35.8M raised with Amgen Ventures backing advancing KR-335 toward IND filing.

## Company Overview

Kernal Biologics is a clinical-stage biotech developing AI-designed mRNA therapeutics for cancer and autoimmune diseases — using machine learning to engineer cell-type-specific mRNA sequences that direct therapeutic payloads (including CAR-T gene programs) to the right cells in vivo, enabling off-the-shelf CAR-T cancer therapy without the individualized cell extraction and ex vivo manufacturing process that makes current CAR-T treatments cost $400,000+ and require weeks of production time. The Y Combinator-backed company has raised $35.8 million including a $25 million Series A led by Hummingbird Ventures with participation from Amgen Ventures.

Kernal's platform analyzes transcriptome data to identify cell-type-specific RNA regulatory elements — promoters, UTRs, and expression signals that direct which cell types will take up and express a given mRNA. By engineering these regulatory elements using ML-guided design, Kernal can create mRNA constructs that preferentially express in specific cell populations (T cells, B cells, macrophages) after systemic delivery, enabling CAR-T programs to work without ex vivo cell collection. The lead program KR-335 is advancing toward IND filing for immuno-oncology indication.

In 2025, Kernal competes in the mRNA therapeutics and cell therapy market with Moderna, BioNTech, and In Vivo Therapeutics for next-generation mRNA platforms, and with Beam Therapeutics, Prime Medicine, and other ex vivo CAR-T developers for the oncology and autoimmune indication space. The promise of in vivo CAR-T — delivering a gene therapy injection that programs the patient's own immune cells to fight cancer — represents a potential transformation of a $20B+ CAR-T market by eliminating the manufacturing complexity. Amgen Ventures' participation signals pharma interest in next-generation cell therapy platforms. The 2025 strategy focuses on advancing KR-335 toward clinical trials, building the mRNA design platform evidence base, and exploring partnership opportunities with larger biopharma companies for CAR-T and autoimmune indications.

## Frequently Asked Questions

### What is Kernal Biologics?
Kernal Biologics is a healthcare technology company founded in 2018 that develops mRNA 2.0 therapeutics for cancer and auto-immune diseases. The company uses AI-powered technology to create cell-specific mRNA therapies that enable scalable in vivo CAR-T treatments.

### What products and services does Kernal Biologics offer?
Kernal Biologics offers mRNA therapeutics, in vivo CAR-T therapies, AI-powered drug design, cell-specific mRNA delivery, and immuno-oncology treatments. Their lead candidate KR-335 is currently being prepared for IND filing.

### Who are Kernal Biologics' target customers?
Kernal Biologics develops therapies for patients with cancer and auto-immune diseases. Their treatments are designed to provide scalable CAR-T therapy options for these patient populations.

### When was Kernal Biologics founded?
Kernal Biologics was founded in 2018. The company participated in Y Combinator's Winter 2020 (W20) batch.

### Where is Kernal Biologics located?
Kernal Biologics is based in San Francisco, California.

### How much funding has Kernal Biologics raised?
Kernal Biologics has raised $35.8M in total funding across 5 rounds from 21 investors. Their Series A round of $25M was completed in February 2022, led by Hummingbird Ventures with participation from Amgen Ventures, HBM Genomics, Civilization Ventures, and other investors.

### What are Kernal Biologics' key achievements?
Kernal Biologics successfully raised $35.8M from prominent investors including Amgen Ventures and completed Y Combinator W20. The company is currently preparing to file an IND for their immuno-oncology candidate KR-335.

### What technology does Kernal Biologics use?
Kernal Biologics uses a machine learning-backed computational pipeline that analyzes transcriptome and translatome datasets to discover cell-specific mRNA sequence features. This AI-powered approach enables the design of cell-specific therapeutic mRNAs through their mRNA 2.0 platform.

### How does Kernal Biologics' mRNA 2.0 platform work?
The mRNA 2.0 platform analyzes datasets across cell types and disease states to identify cell-specific mRNA sequence features. These features are then deployed during synthetic mRNA design to create therapeutics that can be delivered to target cells for in vivo CAR-T therapies.

### What are Kernal Biologics' recent developments?
Kernal Biologics recently raised a $25M Series A in February 2022 led by Hummingbird Ventures. The company is using this capital to extend their mRNA 2.0 platform and support an IND filing for their immuno-oncology candidate KR-335.

## Tags

healthtech, analytics, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*